Abeona Therapeutics Inc. Receives Stockholder Approval for Equity Incentive Plan Amendment

Abeona Therapeutics Inc. has announced that its stockholders have approved the Second Amended and Restated Abeona Therapeutics Inc. 2023 Equity Incentive Plan, known as the Second A&R Plan. The approval took place during a special meeting of stockholders on December 20, 2024.

The Board of Directors had initially approved this plan on November 1, 2024, based on a recommendation from the Compensation Committee, but it was contingent upon receiving consent from stockholders.

The updated Second A&R Plan changes the number of common shares that can be issued. The limit has been raised from 3,200,000 shares to 8,400,000 shares. However, it’s important to mention that the outline provided here does not cover the complete details of the plan. Anyone interested in more information can find the full text attached as Appendix A to the Company's definitive proxy statement filed with the U.S. Securities and Exchange Commission on November 12, 2024, and referred to as Exhibit 10.1.

During the virtual meeting on December 20, a quorum was established, with 24,567,979 shares represented out of a total of 43,593,484 that were eligible to vote. The stockholders then voted in favor of Proposal 1, which involved the increase in shares under the Second A&R Plan. The voting results were 20,996,641 in favor, 2,876,261 against, and 695,077 abstentions. Notably, there were no broker non-votes recorded.

A separate proposal regarding the potential adjournment of the Special Meeting, Proposal 2, was not brought before the stockholders since a quorum was already established with the preliminary results indicating the approval of Proposal 1.

Following the approval of the changes, Abeona Therapeutics has made the Second Amended and Restated Abeona Therapeutics Inc. 2023 Equity Incentive Plan available as Exhibit 10.1. Additionally, the Cover Page Interactive Data File is embedded within the Inline XBRL document and included as Exhibit 104.

The official form was signed by Joseph Vazzano, the Chief Financial Officer of Abeona Therapeutics Inc., on December 20, 2024.

This announcement was generated by an automated content engine but reviewed by a human editor. For more detailed information, one can refer to Abeona Therapeutics’s 8K filing.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company that is dedicated to developing and delivering gene therapy products aimed at treating severe and life-threatening rare diseases. The company’s leading programs include EB-101, which consists of gene-corrected skin grafts for treating recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, an AAV-based gene therapy for Sanfilippo syndrome type A; and ABO-101, also an AAV-based gene therapy for Sanfilippo syndrome type B.

Approval, Equity, Plan, Shares, Stockholders